Cargando…
The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
SIMPLE SUMMARY: Controlled clinical trials are one of the most important sources of medical knowledge, but their results are not always identical to those observed later in normal day-to-day practice. Therefore, real-world studies are needed to investigate those differences. The targeted agents cetu...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487009/ https://www.ncbi.nlm.nih.gov/pubmed/37686636 http://dx.doi.org/10.3390/cancers15174361 |
_version_ | 1785103133162078208 |
---|---|
author | Potocki, Paweł Michał Wiśniowski, Rafał Haus, Dominik Chowaniec, Zbyszko Kozaczka, Maciej Kustra, Magdalena Samborska-Plewicka, Marzenna Szweda, Marcin Starzyczny-Słota, Danuta Michalik, Magdalena Słomian, Grzegorz Lebiedzińska, Aneta Jonak-Olczyk, Natalia Łaszewska-Kraińska, Natalia Adamowicz, Krzysztof Kolenda, Piotr Drosik-Kwaśniewska, Anna Szwiec, Marek Dziura, Robert Czech, Justyna Dąbrowska, Maria Nowakowska-Zajdel, Ewa Klank-Sokołowska, Ewa Konopka, Kamil Kwinta, Łukasz Dobrzańska, Jolanta Wysocki, Piotr J. |
author_facet | Potocki, Paweł Michał Wiśniowski, Rafał Haus, Dominik Chowaniec, Zbyszko Kozaczka, Maciej Kustra, Magdalena Samborska-Plewicka, Marzenna Szweda, Marcin Starzyczny-Słota, Danuta Michalik, Magdalena Słomian, Grzegorz Lebiedzińska, Aneta Jonak-Olczyk, Natalia Łaszewska-Kraińska, Natalia Adamowicz, Krzysztof Kolenda, Piotr Drosik-Kwaśniewska, Anna Szwiec, Marek Dziura, Robert Czech, Justyna Dąbrowska, Maria Nowakowska-Zajdel, Ewa Klank-Sokołowska, Ewa Konopka, Kamil Kwinta, Łukasz Dobrzańska, Jolanta Wysocki, Piotr J. |
author_sort | Potocki, Paweł Michał |
collection | PubMed |
description | SIMPLE SUMMARY: Controlled clinical trials are one of the most important sources of medical knowledge, but their results are not always identical to those observed later in normal day-to-day practice. Therefore, real-world studies are needed to investigate those differences. The targeted agents cetuximab and panitumumab, combined with chemotherapy, are an effective treatment for metastatic colon cancer, provided that certain mutations have not occurred in cancer cells (namely activating mutations in KRAS, NRAS or BRAF genes). Recently, it was found that the outcomes of the aforementioned therapy differ depending on which part of the colon the tumour originates from. We conducted a real-world study on 842 patients treated at 16 cancer centres. The study confirmed that metastatic cancer that originated in the right part of the colon has a lower response to cetuximab or panitumumab-based treatment. ABSTRACT: Anti-EGFR antibodies combined with chemotherapy doublets are a cornerstone of the upfront treatment of colorectal cancer. RAS and BRAF mutations are established negative predictive factors for such therapy. The primary tumour located in the proximal colon has recently emerged as another negative predictive factor. We have conducted a retrospective multicentre study to collect data on real-world population characteristics, practice patterns, and outcomes in patients with metastatic colorectal cancer treated in a first-line setting with either cetuximab or panitumumab in combination with either FOLFOX or FOLFIRI chemotherapy. The presented analysis focuses on the impact of the primary tumour location. 126 of 842 patients analysed (15.0%) had proximal primary. It was associated with a lower BMI at diagnosis, mucinous histology, and peritoneal metastases. It was also associated with inferior treatment outcomes in terms of response ratio: 59.4% vs. 74.22% (odds ratio [OR] 0.51, 95% CI 0.33–0.78, p = 0.010), and median depth of response: −36.7% vs. −50.0% (p = 0.038). There was only a borderline non-significant trend for inferior PFS in patients with proximal tumours. OS data was incomplete. The presented analysis confirms the negative impact of tumour sidedness on the efficacy of an upfront anti-EGFR-chemotherapy combination and provides valuable data on real-world population characteristics. |
format | Online Article Text |
id | pubmed-10487009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104870092023-09-09 The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER) Potocki, Paweł Michał Wiśniowski, Rafał Haus, Dominik Chowaniec, Zbyszko Kozaczka, Maciej Kustra, Magdalena Samborska-Plewicka, Marzenna Szweda, Marcin Starzyczny-Słota, Danuta Michalik, Magdalena Słomian, Grzegorz Lebiedzińska, Aneta Jonak-Olczyk, Natalia Łaszewska-Kraińska, Natalia Adamowicz, Krzysztof Kolenda, Piotr Drosik-Kwaśniewska, Anna Szwiec, Marek Dziura, Robert Czech, Justyna Dąbrowska, Maria Nowakowska-Zajdel, Ewa Klank-Sokołowska, Ewa Konopka, Kamil Kwinta, Łukasz Dobrzańska, Jolanta Wysocki, Piotr J. Cancers (Basel) Article SIMPLE SUMMARY: Controlled clinical trials are one of the most important sources of medical knowledge, but their results are not always identical to those observed later in normal day-to-day practice. Therefore, real-world studies are needed to investigate those differences. The targeted agents cetuximab and panitumumab, combined with chemotherapy, are an effective treatment for metastatic colon cancer, provided that certain mutations have not occurred in cancer cells (namely activating mutations in KRAS, NRAS or BRAF genes). Recently, it was found that the outcomes of the aforementioned therapy differ depending on which part of the colon the tumour originates from. We conducted a real-world study on 842 patients treated at 16 cancer centres. The study confirmed that metastatic cancer that originated in the right part of the colon has a lower response to cetuximab or panitumumab-based treatment. ABSTRACT: Anti-EGFR antibodies combined with chemotherapy doublets are a cornerstone of the upfront treatment of colorectal cancer. RAS and BRAF mutations are established negative predictive factors for such therapy. The primary tumour located in the proximal colon has recently emerged as another negative predictive factor. We have conducted a retrospective multicentre study to collect data on real-world population characteristics, practice patterns, and outcomes in patients with metastatic colorectal cancer treated in a first-line setting with either cetuximab or panitumumab in combination with either FOLFOX or FOLFIRI chemotherapy. The presented analysis focuses on the impact of the primary tumour location. 126 of 842 patients analysed (15.0%) had proximal primary. It was associated with a lower BMI at diagnosis, mucinous histology, and peritoneal metastases. It was also associated with inferior treatment outcomes in terms of response ratio: 59.4% vs. 74.22% (odds ratio [OR] 0.51, 95% CI 0.33–0.78, p = 0.010), and median depth of response: −36.7% vs. −50.0% (p = 0.038). There was only a borderline non-significant trend for inferior PFS in patients with proximal tumours. OS data was incomplete. The presented analysis confirms the negative impact of tumour sidedness on the efficacy of an upfront anti-EGFR-chemotherapy combination and provides valuable data on real-world population characteristics. MDPI 2023-09-01 /pmc/articles/PMC10487009/ /pubmed/37686636 http://dx.doi.org/10.3390/cancers15174361 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Potocki, Paweł Michał Wiśniowski, Rafał Haus, Dominik Chowaniec, Zbyszko Kozaczka, Maciej Kustra, Magdalena Samborska-Plewicka, Marzenna Szweda, Marcin Starzyczny-Słota, Danuta Michalik, Magdalena Słomian, Grzegorz Lebiedzińska, Aneta Jonak-Olczyk, Natalia Łaszewska-Kraińska, Natalia Adamowicz, Krzysztof Kolenda, Piotr Drosik-Kwaśniewska, Anna Szwiec, Marek Dziura, Robert Czech, Justyna Dąbrowska, Maria Nowakowska-Zajdel, Ewa Klank-Sokołowska, Ewa Konopka, Kamil Kwinta, Łukasz Dobrzańska, Jolanta Wysocki, Piotr J. The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER) |
title | The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER) |
title_full | The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER) |
title_fullStr | The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER) |
title_full_unstemmed | The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER) |
title_short | The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER) |
title_sort | impact of sidedness on the efficacy of anti-egfr-based first-line chemotherapy in advanced colorectal cancer patients in real-life setting—a nation-wide retrospective analysis (racer) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487009/ https://www.ncbi.nlm.nih.gov/pubmed/37686636 http://dx.doi.org/10.3390/cancers15174361 |
work_keys_str_mv | AT potockipawełmichał theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT wisniowskirafał theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT hausdominik theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT chowanieczbyszko theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT kozaczkamaciej theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT kustramagdalena theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT samborskaplewickamarzenna theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT szwedamarcin theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT starzycznysłotadanuta theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT michalikmagdalena theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT słomiangrzegorz theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT lebiedzinskaaneta theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT jonakolczyknatalia theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT łaszewskakrainskanatalia theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT adamowiczkrzysztof theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT kolendapiotr theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT drosikkwasniewskaanna theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT szwiecmarek theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT dziurarobert theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT czechjustyna theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT dabrowskamaria theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT nowakowskazajdelewa theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT klanksokołowskaewa theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT konopkakamil theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT kwintałukasz theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT dobrzanskajolanta theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT wysockipiotrj theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT potockipawełmichał impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT wisniowskirafał impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT hausdominik impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT chowanieczbyszko impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT kozaczkamaciej impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT kustramagdalena impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT samborskaplewickamarzenna impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT szwedamarcin impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT starzycznysłotadanuta impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT michalikmagdalena impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT słomiangrzegorz impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT lebiedzinskaaneta impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT jonakolczyknatalia impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT łaszewskakrainskanatalia impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT adamowiczkrzysztof impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT kolendapiotr impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT drosikkwasniewskaanna impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT szwiecmarek impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT dziurarobert impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT czechjustyna impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT dabrowskamaria impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT nowakowskazajdelewa impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT klanksokołowskaewa impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT konopkakamil impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT kwintałukasz impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT dobrzanskajolanta impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer AT wysockipiotrj impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer |